Role of microtubule affinity‐regulating kinases in epilepsy: A novel therapeutic strategy
British Journal of Pharmacology · 2026-06 · 183 (11) · 2990-3014
DOI: 10.1111/bph.70354 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 19.02.2026. Verfasst von Min Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Epilepsy, Protein Serine-Threonine Kinases, Protein Kinase Inhibitors. Die Arbeit nennt 65 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Major Basic Research Special Projects of Shandong Provincial, China.
Abstract (Originalsprache)
Background and Purpose Microtubule affinity‐regulating kinases (MARKs), implicated in synaptic remodelling processes, have attracted attention as key regulatory targets in numerous neurological and psychiatric disorders. However, their role in epilepsy remains unclear. This study examined the involvement of MARK1 or MARK2 in regulating epilepsy‐induced synaptic plasticity. Experimental Approach The roles of MARKs in normal or epilepsy rats were evaluated through hippocampus CA1 region‐specific gene knockdown or overexpression of MARK1 or MARK2, as well as systemic administration of the novel small‐molecule MARK inhibitor, PCC0105003. Cognitive functions and anxiety‐like behaviours were assessed in epileptic rats. Synaptic plasticity‐related signalling changes were detected via western blots, immunofluorescence, and quantitative real‐time polymerase chain reaction (qRT‐PCR). Key Results Epileptiform discharges were observed in EEGs of rats overexpressing MARK1 or MARK2 in the absence of chemoconvulsant‐induced epilepsy. MARK1 or MARK2 knockdown in hippocampus CA1 and systemic administration of PCC0105003 ameliorated seizure behaviours and the number of seizure‐like events (SLEs) in EEG recordings, and attenuated the cognitive deficit and anxiogenic‐like behaviours. In contrast, overexpression of MARK1 or MARK2 in the hippocampus CA1 led to exacerbated epileptic‐like behaviours and reduced therapeutic effects of PCC0105003. Blocking the signalling of MARKs likely led to a reversal of synaptic transmission, which was mediated by the suppression of NMDA2B/GluR1/CAMKII signalling pathway in epileptic rats. Conclusion and Implications MARK1/2‐mediated excitatory synaptic transmission plays a key role in the development of epilepsy. Pharmacological inhibitors of MARKs, such as PCC0105003, may represent a novel therapeutic strategy for the management of epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
- State Key Laboratory of Advanced Drug Delivery and Release Systems, Yantai, China.
Förderung
- Natural Science Foundation of Shandong Province
- Major Basic Research Special Projects of Shandong Provincial, China
Zitieren
APA
Xu, M., Shi, Y., Mu, X., Su, C., Wei, P., Wang, Q., Zhang, Y., Ji, S., Fu, C., Tian, J., & Li, C. (2026). Role of microtubule affinity‐regulating kinases in epilepsy: A novel therapeutic strategy. British Journal of Pharmacology, 183(11), 2990-3014. https://doi.org/10.1111/bph.70354
Vancouver
Xu M, Shi Y, Mu X, Su C, Wei P, Wang Q, et al. Role of microtubule affinity‐regulating kinases in epilepsy: A novel therapeutic strategy. British Journal of Pharmacology. 2026;183(11):2990-3014. doi:10.1111/bph.70354
BibTeX
@article{Xu2026,
author = {Xu, Min and Shi, Yaoqin and Mu, Xinxin and Su, Chunyu and Wei, Pengcheng and Wang, Qian and Zhang, Yingtian and Ji, Shengmin and Fu, Chenyu and Tian, Jingwei and Li, Chunmei},
title = {Role of microtubule affinity‐regulating kinases in epilepsy: A novel therapeutic strategy},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {11},
pages = {2990--3014},
doi = {10.1111/bph.70354}
}
EUVIMED